Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...
Zacks.com on MSN18h
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?
AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
The Globe and Mail27m
3 Oversold Dividend Aristocrats Ready To Explode in 2025
AbbVie Inc. is a global biopharmaceutical company known for researching, developing, and commercializing advanced therapies for various diseases. The company developed Humira, one of the best-selling ...
BioSpace20h
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...
Managed Healthcare Executive13h
VA Adds Cancer Immunotherapy Monjuvi to National Formulary
Monjuvi is available under an accelerated approval to treat adults with relapsed or refractory diffuse large B-cell lymphoma.